Selected research
Market Outlook & Growth Opportunities
Global Radioisotopes in Medicine Market Outlook and Growth Opportunities 2026
Market perspective
The global Radioisotopes in Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Radioisotopes in Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Radioisotopes in Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Radioisotopes in Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Radioisotopes in Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Radioisotopes in Medicine market include ANSTO, China National Nuclear Corporation, Eckert & Ziegler Strahlen, IRE, Nordion, NorthStar Medical Radioisotopes, NRG, NTP Radioisotopes and Polatom, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Radioisotopes in Medicine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Radioisotopes in Medicine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Radioisotopes in Medicine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Radioisotopes in Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.
Radioisotopes in Medicine Segment by Company
ANSTO
China National Nuclear Corporation
Eckert & Ziegler Strahlen
IRE
Nordion
NorthStar Medical Radioisotopes
NRG
NTP Radioisotopes
Polatom
Rosatom
SHINE Technologies
Radioisotopes in Medicine Segment by Type
Tc-99m
Iodine Radioisotopes
Cobalt-60
Others
Radioisotopes in Medicine Segment by Application
Nuclear Therapy
Equipment Radioactive Source
Diagnosis
Radioisotopes in Medicine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Radioisotopes in Medicine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Radioisotopes in Medicine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Radioisotopes in Medicine significant trends, drivers, influence factors in global and regions.
6. To analyze Radioisotopes in Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radioisotopes in Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radioisotopes in Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radioisotopes in Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Radioisotopes in Medicine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radioisotopes in Medicine industry.
Chapter 3: Detailed analysis of Radioisotopes in Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Radioisotopes in Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Radioisotopes in Medicine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Tc-99m
- Iodine Radioisotopes
- Cobalt-60
- Others
Applications
- Nuclear Therapy
- Equipment Radioactive Source
- Diagnosis
Companies covered
- ANSTO
- China National Nuclear Corporation
- Eckert & Ziegler Strahlen
- IRE
- Nordion
- NorthStar Medical Radioisotopes
- NRG
- NTP Radioisotopes
- Polatom
- Rosatom
- SHINE Technologies
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Radioisotopes in Medicine Sales Value (2021-2032)
- 1.2.2 Global Radioisotopes in Medicine Sales Volume (2021-2032)
- 1.2.3 Global Radioisotopes in Medicine Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Radioisotopes in Medicine Market Dynamics
- 2.1 Radioisotopes in Medicine Industry Trends
- 2.2 Radioisotopes in Medicine Industry Drivers
- 2.3 Radioisotopes in Medicine Industry Opportunities and Challenges
- 2.4 Radioisotopes in Medicine Industry Restraints
3 Radioisotopes in Medicine Market by Company
- 3.1 Global Radioisotopes in Medicine Company Revenue Ranking in 2025
- 3.2 Global Radioisotopes in Medicine Revenue by Company (2021-2026)
- 3.3 Global Radioisotopes in Medicine Sales Volume by Company (2021-2026)
- 3.4 Global Radioisotopes in Medicine Average Price by Company (2021-2026)
- 3.5 Global Radioisotopes in Medicine Company Ranking (2024-2026)
- 3.6 Global Radioisotopes in Medicine Company Manufacturing Base and Headquarters
- 3.7 Global Radioisotopes in Medicine Company Product Type and Application
- 3.8 Global Radioisotopes in Medicine Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Radioisotopes in Medicine Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Radioisotopes in Medicine Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Radioisotopes in Medicine Market by Type
- 4.1 Radioisotopes in Medicine Type Introduction
- 4.1.1 Tc-99m
- 4.1.2 Iodine Radioisotopes
- 4.1.3 Cobalt-60
- 4.1.4 Others
- 4.2 Global Radioisotopes in Medicine Sales Volume by Type
- 4.2.1 Global Radioisotopes in Medicine Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Radioisotopes in Medicine Sales Volume by Type (2021-2032)
- 4.2.3 Global Radioisotopes in Medicine Sales Volume Share by Type (2021-2032)
- 4.3 Global Radioisotopes in Medicine Sales Value by Type
- 4.3.1 Global Radioisotopes in Medicine Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Radioisotopes in Medicine Sales Value by Type (2021-2032)
- 4.3.3 Global Radioisotopes in Medicine Sales Value Share by Type (2021-2032)
5 Radioisotopes in Medicine Market by Application
- 5.1 Radioisotopes in Medicine Application Introduction
- 5.1.1 Nuclear Therapy
- 5.1.2 Equipment Radioactive Source
- 5.1.3 Diagnosis
- 5.2 Global Radioisotopes in Medicine Sales Volume by Application
- 5.2.1 Global Radioisotopes in Medicine Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Radioisotopes in Medicine Sales Volume by Application (2021-2032)
- 5.2.3 Global Radioisotopes in Medicine Sales Volume Share by Application (2021-2032)
- 5.3 Global Radioisotopes in Medicine Sales Value by Application
- 5.3.1 Global Radioisotopes in Medicine Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Radioisotopes in Medicine Sales Value by Application (2021-2032)
- 5.3.3 Global Radioisotopes in Medicine Sales Value Share by Application (2021-2032)
6 Radioisotopes in Medicine Regional Sales and Value Analysis
- 6.1 Global Radioisotopes in Medicine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Radioisotopes in Medicine Sales by Region (2021-2032)
- 6.2.1 Global Radioisotopes in Medicine Sales by Region: 2021-2026
- 6.2.2 Global Radioisotopes in Medicine Sales by Region (2027-2032)
- 6.3 Global Radioisotopes in Medicine Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Radioisotopes in Medicine Sales Value by Region (2021-2032)
- 6.4.1 Global Radioisotopes in Medicine Sales Value by Region: 2021-2026
- 6.4.2 Global Radioisotopes in Medicine Sales Value by Region (2027-2032)
- 6.5 Global Radioisotopes in Medicine Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Radioisotopes in Medicine Sales Value (2021-2032)
- 6.6.2 North America Radioisotopes in Medicine Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Radioisotopes in Medicine Sales Value (2021-2032)
- 6.7.2 Europe Radioisotopes in Medicine Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Radioisotopes in Medicine Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Radioisotopes in Medicine Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Radioisotopes in Medicine Sales Value (2021-2032)
- 6.9.2 South America Radioisotopes in Medicine Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Radioisotopes in Medicine Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Radioisotopes in Medicine Sales Value Share by Country, 2025 VS 2032
7 Radioisotopes in Medicine Country-level Sales and Value Analysis
- 7.1 Global Radioisotopes in Medicine Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Radioisotopes in Medicine Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Radioisotopes in Medicine Sales by Country (2021-2032)
- 7.3.1 Global Radioisotopes in Medicine Sales by Country (2021-2026)
- 7.3.2 Global Radioisotopes in Medicine Sales by Country (2027-2032)
- 7.4 Global Radioisotopes in Medicine Sales Value by Country (2021-2032)
- 7.4.1 Global Radioisotopes in Medicine Sales Value by Country (2021-2026)
- 7.4.2 Global Radioisotopes in Medicine Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.9.2 France Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.16.2 China Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.19.2 India Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Radioisotopes in Medicine Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Radioisotopes in Medicine Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Radioisotopes in Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 ANSTO
- 8.1.1 ANSTO Company Information
- 8.1.2 ANSTO Business Overview
- 8.1.3 ANSTO Radioisotopes in Medicine Sales, Value and Gross Margin (2021-2026)
- 8.1.4 ANSTO Radioisotopes in Medicine Product Portfolio
- 8.1.5 ANSTO Recent Developments
- 8.2 China National Nuclear Corporation
- 8.2.1 China National Nuclear Corporation Company Information
- 8.2.2 China National Nuclear Corporation Business Overview
- 8.2.3 China National Nuclear Corporation Radioisotopes in Medicine Sales, Value and Gross Margin (2021-2026)
- 8.2.4 China National Nuclear Corporation Radioisotopes in Medicine Product Portfolio
- 8.2.5 China National Nuclear Corporation Recent Developments
- 8.3 Eckert & Ziegler Strahlen
- 8.3.1 Eckert & Ziegler Strahlen Company Information
- 8.3.2 Eckert & Ziegler Strahlen Business Overview
- 8.3.3 Eckert & Ziegler Strahlen Radioisotopes in Medicine Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Eckert & Ziegler Strahlen Radioisotopes in Medicine Product Portfolio
- 8.3.5 Eckert & Ziegler Strahlen Recent Developments
- 8.4 IRE
- 8.4.1 IRE Company Information
- 8.4.2 IRE Business Overview
- 8.4.3 IRE Radioisotopes in Medicine Sales, Value and Gross Margin (2021-2026)
- 8.4.4 IRE Radioisotopes in Medicine Product Portfolio
- 8.4.5 IRE Recent Developments
- 8.5 Nordion
- 8.5.1 Nordion Company Information
- 8.5.2 Nordion Business Overview
- 8.5.3 Nordion Radioisotopes in Medicine Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Nordion Radioisotopes in Medicine Product Portfolio
- 8.5.5 Nordion Recent Developments
- 8.6 NorthStar Medical Radioisotopes
- 8.6.1 NorthStar Medical Radioisotopes Company Information
- 8.6.2 NorthStar Medical Radioisotopes Business Overview
- 8.6.3 NorthStar Medical Radioisotopes Radioisotopes in Medicine Sales, Value and Gross Margin (2021-2026)
- 8.6.4 NorthStar Medical Radioisotopes Radioisotopes in Medicine Product Portfolio
- 8.6.5 NorthStar Medical Radioisotopes Recent Developments
- 8.7 NRG
- 8.7.1 NRG Company Information
- 8.7.2 NRG Business Overview
- 8.7.3 NRG Radioisotopes in Medicine Sales, Value and Gross Margin (2021-2026)
- 8.7.4 NRG Radioisotopes in Medicine Product Portfolio
- 8.7.5 NRG Recent Developments
- 8.8 NTP Radioisotopes
- 8.8.1 NTP Radioisotopes Company Information
- 8.8.2 NTP Radioisotopes Business Overview
- 8.8.3 NTP Radioisotopes Radioisotopes in Medicine Sales, Value and Gross Margin (2021-2026)
- 8.8.4 NTP Radioisotopes Radioisotopes in Medicine Product Portfolio
- 8.8.5 NTP Radioisotopes Recent Developments
- 8.9 Polatom
- 8.9.1 Polatom Company Information
- 8.9.2 Polatom Business Overview
- 8.9.3 Polatom Radioisotopes in Medicine Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Polatom Radioisotopes in Medicine Product Portfolio
- 8.9.5 Polatom Recent Developments
- 8.10 Rosatom
- 8.10.1 Rosatom Company Information
- 8.10.2 Rosatom Business Overview
- 8.10.3 Rosatom Radioisotopes in Medicine Sales, Value and Gross Margin (2021-2026)
- 8.10.4 Rosatom Radioisotopes in Medicine Product Portfolio
- 8.10.5 Rosatom Recent Developments
- 8.11 SHINE Technologies
- 8.11.1 SHINE Technologies Company Information
- 8.11.2 SHINE Technologies Business Overview
- 8.11.3 SHINE Technologies Radioisotopes in Medicine Sales, Value and Gross Margin (2021-2026)
- 8.11.4 SHINE Technologies Radioisotopes in Medicine Product Portfolio
- 8.11.5 SHINE Technologies Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Radioisotopes in Medicine Value Chain Analysis
- 9.1.1 Radioisotopes in Medicine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Radioisotopes in Medicine Sales Mode & Process
- 9.2 Radioisotopes in Medicine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Radioisotopes in Medicine Distributors
- 9.2.3 Radioisotopes in Medicine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst